Article
Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
PloS one - 1 Jan 2021
Suenaga Riichiro, Suka Machi, Hirao Tomohiro, Hidaka Isao, Sakaida Isao, Ishida Haku
Abstract excerpt
AIM: To evaluate the cost-effectiveness of therapeutic strategies initiated at different stages of liver fibrosis using three direct-acting antivirals (DAAs), sofosbuvir-ledipasvir (SL), glecaprevir-pibrentasvir (GP), and elbasvir plus grazoprevir (E/G), for Japanese patients with chronic hepatitis C (CHC) genotype 1. METHODS: We created an analytical decision model reflecting the progression of liver fibrosis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.